Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

Condition(s) targeted: Amphetamine-Related Disorders

Intervention: Selegiline (Drug)

Phase: Phase 1

Status: Active, not recruiting

Sponsored by: National Institute on Drug Abuse (NIDA)

Official(s) and/or principal investigator(s):
Thomas Newton, M.D., Principal Investigator, Affiliation: University of California, Los Angeles

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Official title: Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline

Study design: Treatment, Randomized, Single Blind, Placebo Control

Primary outcome:

safety of selegiline

pharmacokinetic assessment

Detailed description: To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i. v. with the focus being on cardiovascular responses (HR,BP) to the i. v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i. v. methamphetamine challenges.

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence;

non-treatment seeking individuals

- Be able to verbalize understanding of consent form; provide written informed consent

Exclusion Criteria:

- Please contact site for more information

UCLA Integrated Substance Abuse Program, Los Angeles, California 90024, United States

Starting date: September 2001
Ending date: October 2002
Last updated: October 23, 2007